Edgar V. Lerma 🇵🇭
@edgarvlermamd.bsky.social
Chicago Sports Fan... Nephrologist by day. My tweets are not medical advice. The views expressed here are my own and not those of my employer
Pinned
Reposted by Edgar V. Lerma 🇵🇭
Role of #Mitochondrial #AKT1 Signaling in #Renal #Tubular Injury of Metabolic Syndrome
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
January 3, 2025 at 3:00 PM
Role of #Mitochondrial #AKT1 Signaling in #Renal #Tubular Injury of Metabolic Syndrome
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
Reposted by Edgar V. Lerma 🇵🇭
Outcomes for Patients With a Deceased #Donor Kidney Offer in the New #Allocation System
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
January 29, 2025 at 3:00 PM
Outcomes for Patients With a Deceased #Donor Kidney Offer in the New #Allocation System
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
#VisualAbstract by @edgarvlermamd
www.kireports.org/ar...
Reposted by Edgar V. Lerma 🇵🇭
#LowEnergy Diets for #Obesity and #CKD (SLOW-CKD Randomized Feasibility Study)
#VIsualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
#VIsualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
June 4, 2025 at 3:00 PM
#LowEnergy Diets for #Obesity and #CKD (SLOW-CKD Randomized Feasibility Study)
#VIsualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
#VIsualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
Reposted by Edgar V. Lerma 🇵🇭
#Complement Proteins Identify Rapidly Progressive #Diabetic Kidney Disease #DKD
#VisualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
#VisualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
June 30, 2025 at 3:00 PM
#Complement Proteins Identify Rapidly Progressive #Diabetic Kidney Disease #DKD
#VisualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
#VisualAbstract by @edgarvlermamd.bsky.social
www.kireports.org/ar...
Reposted by Edgar V. Lerma 🇵🇭
#Infliximab for Grade III/IV #ICI #Nephritis Clinical and Translational Evidence
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00662-X/fulltext
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00662-X/fulltext
November 7, 2025 at 2:01 PM
#Infliximab for Grade III/IV #ICI #Nephritis Clinical and Translational Evidence
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00662-X/fulltext
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00662-X/fulltext
Reposted by Edgar V. Lerma 🇵🇭
#Biomarker Prediction of Delayed Graft Function #DGF and Prognosis Post-kidney #Transplantation
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00665-5/fulltext
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00665-5/fulltext
November 21, 2025 at 2:00 PM
#Biomarker Prediction of Delayed Graft Function #DGF and Prognosis Post-kidney #Transplantation
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00665-5/fulltext
#VisualAbstract by Edgar V. Lerma 🇵🇭
https://www.kireports.org/article/S2468-0249(25)00665-5/fulltext
Testing for the Best Biomarker 🧪 in IgA Nephropathy #IgAN ca. 2025 from @asnpublications.bsky.social
#Nephpearls
Editorial by Dr Richard Lafayette 👉 pubmed.ncbi.nlm.nih.gov/41066174/
#VisualAbstract by @hellokidneymd.bsky.social
👉 pubmed.ncbi.nlm.nih.gov/40924482/
#Nephpearls
Editorial by Dr Richard Lafayette 👉 pubmed.ncbi.nlm.nih.gov/41066174/
#VisualAbstract by @hellokidneymd.bsky.social
👉 pubmed.ncbi.nlm.nih.gov/40924482/
November 16, 2025 at 4:02 AM
Testing for the Best Biomarker 🧪 in IgA Nephropathy #IgAN ca. 2025 from @asnpublications.bsky.social
#Nephpearls
Editorial by Dr Richard Lafayette 👉 pubmed.ncbi.nlm.nih.gov/41066174/
#VisualAbstract by @hellokidneymd.bsky.social
👉 pubmed.ncbi.nlm.nih.gov/40924482/
#Nephpearls
Editorial by Dr Richard Lafayette 👉 pubmed.ncbi.nlm.nih.gov/41066174/
#VisualAbstract by @hellokidneymd.bsky.social
👉 pubmed.ncbi.nlm.nih.gov/40924482/
BAFF and APRIL represent pre-HIT 1 in #IgAN
#Nephpearls #NephSky
Antigen-driven immune activation within lymphoid tissues leads to the release of BAFF and APRIL, which bind to those receptors and promote B-cell survival and production of IgA
👉🏼 pubmed.ncbi.nlm.nih.gov/38362118/
#Nephpearls #NephSky
Antigen-driven immune activation within lymphoid tissues leads to the release of BAFF and APRIL, which bind to those receptors and promote B-cell survival and production of IgA
👉🏼 pubmed.ncbi.nlm.nih.gov/38362118/
November 15, 2025 at 8:36 AM
BAFF and APRIL represent pre-HIT 1 in #IgAN
#Nephpearls #NephSky
Antigen-driven immune activation within lymphoid tissues leads to the release of BAFF and APRIL, which bind to those receptors and promote B-cell survival and production of IgA
👉🏼 pubmed.ncbi.nlm.nih.gov/38362118/
#Nephpearls #NephSky
Antigen-driven immune activation within lymphoid tissues leads to the release of BAFF and APRIL, which bind to those receptors and promote B-cell survival and production of IgA
👉🏼 pubmed.ncbi.nlm.nih.gov/38362118/
According to ChatGPT, the “four-hit” (or “4-hit”) hypothesis for IgA nephropathy #IgAN was first clearly articulated by Hitoshi Suzuki et al. in their 2011 J. Am. Soc. Nephrol. paper, “The pathophysiology of IgA nephropathy.”
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/21949093/
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/21949093/
November 15, 2025 at 8:24 AM
According to ChatGPT, the “four-hit” (or “4-hit”) hypothesis for IgA nephropathy #IgAN was first clearly articulated by Hitoshi Suzuki et al. in their 2011 J. Am. Soc. Nephrol. paper, “The pathophysiology of IgA nephropathy.”
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/21949093/
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/21949093/
Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) ca. 2025 from @juancarlosqvelez.bsky.social
#Nephpearls #FSGS #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41222995/
#Nephpearls #FSGS #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41222995/
November 14, 2025 at 3:37 PM
Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) ca. 2025 from @juancarlosqvelez.bsky.social
#Nephpearls #FSGS #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41222995/
#Nephpearls #FSGS #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41222995/
November 12, 2025 at 3:59 PM
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy ca. 2025
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 pubmed.ncbi.nlm.nih.gov/41196369/
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 pubmed.ncbi.nlm.nih.gov/41196369/
November 9, 2025 at 8:10 PM
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy ca. 2025
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 pubmed.ncbi.nlm.nih.gov/41196369/
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 pubmed.ncbi.nlm.nih.gov/41196369/
Sibeprenlimab in IgA Nephropathy: Interim Analysis of a Phase 3 Trial ca. 2025
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 www.nejm.org/doi/full/10....
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 www.nejm.org/doi/full/10....
November 9, 2025 at 5:15 PM
Sibeprenlimab in IgA Nephropathy: Interim Analysis of a Phase 3 Trial ca. 2025
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 www.nejm.org/doi/full/10....
#Nephpearls #KidneyWk #NephSky
#VisualAbstract by @nephroseeker.medsky.social @nephjc.bsky.social
👉🏼 www.nejm.org/doi/full/10....
November 9, 2025 at 2:59 AM
#KidneyWk #HTNSecrets #Nephsecrets #NephSky
@hswapnil.medsky.social @kidneyboy.bsky.social @nephrosparks.bsky.social
@hswapnil.medsky.social @kidneyboy.bsky.social @nephrosparks.bsky.social
November 8, 2025 at 5:37 PM
It’s been a pleasure reconnecting with my mentors from @nu-nephrology.bsky.social Drs Daniel Batlle and Robert Rosa
#KidneyWk #NephSky
🙏🏽 I am forever grateful for their mentorship
✍🏼 My first ever publications were with them
pubmed.ncbi.nlm.nih.gov/11689388/
pubmed.ncbi.nlm.nih.gov/15327401/
#KidneyWk #NephSky
🙏🏽 I am forever grateful for their mentorship
✍🏼 My first ever publications were with them
pubmed.ncbi.nlm.nih.gov/11689388/
pubmed.ncbi.nlm.nih.gov/15327401/
November 8, 2025 at 2:05 PM
It’s been a pleasure reconnecting with my mentors from @nu-nephrology.bsky.social Drs Daniel Batlle and Robert Rosa
#KidneyWk #NephSky
🙏🏽 I am forever grateful for their mentorship
✍🏼 My first ever publications were with them
pubmed.ncbi.nlm.nih.gov/11689388/
pubmed.ncbi.nlm.nih.gov/15327401/
#KidneyWk #NephSky
🙏🏽 I am forever grateful for their mentorship
✍🏼 My first ever publications were with them
pubmed.ncbi.nlm.nih.gov/11689388/
pubmed.ncbi.nlm.nih.gov/15327401/
Indications for mineralocorticoid receptor antagonists (MRAs) in the management of cardio-kidney risk
#KidneyWk #Nephpearls #NephSky #Cardiorenal
✅ Check out this resource from @theisn.org
@isnkidneycare.bsky.social
👉 www.theisn.org/initiatives/...
#KidneyWk #Nephpearls #NephSky #Cardiorenal
✅ Check out this resource from @theisn.org
@isnkidneycare.bsky.social
👉 www.theisn.org/initiatives/...
November 8, 2025 at 12:46 PM
Indications for mineralocorticoid receptor antagonists (MRAs) in the management of cardio-kidney risk
#KidneyWk #Nephpearls #NephSky #Cardiorenal
✅ Check out this resource from @theisn.org
@isnkidneycare.bsky.social
👉 www.theisn.org/initiatives/...
#KidneyWk #Nephpearls #NephSky #Cardiorenal
✅ Check out this resource from @theisn.org
@isnkidneycare.bsky.social
👉 www.theisn.org/initiatives/...
Which patients should be on SGLT2 inhibitors (SGLT2i) ⁉️
✅ Check out the SGLT2i Cold 🥶 Map from @theisn.org
#KidneyWk #Nephpearls
👉🏼 www.theisn.org/initiatives/...
✅ Check out the SGLT2i Cold 🥶 Map from @theisn.org
#KidneyWk #Nephpearls
👉🏼 www.theisn.org/initiatives/...
November 8, 2025 at 12:04 PM
Which patients should be on SGLT2 inhibitors (SGLT2i) ⁉️
✅ Check out the SGLT2i Cold 🥶 Map from @theisn.org
#KidneyWk #Nephpearls
👉🏼 www.theisn.org/initiatives/...
✅ Check out the SGLT2i Cold 🥶 Map from @theisn.org
#KidneyWk #Nephpearls
👉🏼 www.theisn.org/initiatives/...
Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial ca. 2025 from @asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
journals.lww.com/jasn/fulltex...
#Nephpearls #KidneyWk #NephSky
journals.lww.com/jasn/fulltex...
November 7, 2025 at 7:04 PM
Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial ca. 2025 from @asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
journals.lww.com/jasn/fulltex...
#Nephpearls #KidneyWk #NephSky
journals.lww.com/jasn/fulltex...
Is It Time to Consider Population-Based Urine Dipstick Screening for Early Detection of Kidney Disease? ca. 2025 from @kireports.bsky.social @saynanorouzi.bsky.social
#Nephpearls #KidneyWk #NephSky
👉 www.kireports.org/article/S246...
#Nephpearls #KidneyWk #NephSky
👉 www.kireports.org/article/S246...
November 7, 2025 at 2:58 PM
Is It Time to Consider Population-Based Urine Dipstick Screening for Early Detection of Kidney Disease? ca. 2025 from @kireports.bsky.social @saynanorouzi.bsky.social
#Nephpearls #KidneyWk #NephSky
👉 www.kireports.org/article/S246...
#Nephpearls #KidneyWk #NephSky
👉 www.kireports.org/article/S246...
CONFIDENCE (Post hoc): Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both ca. 2025 from
@asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41196655/
@asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41196655/
November 7, 2025 at 1:41 PM
CONFIDENCE (Post hoc): Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both ca. 2025 from
@asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41196655/
@asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41196655/
November 7, 2025 at 12:00 AM
ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives ca. 2025 from @asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/40965988/
#Nephpearls #KidneyWk #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/40965988/
November 6, 2025 at 8:32 PM
ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives ca. 2025 from @asnpublications.bsky.social
#Nephpearls #KidneyWk #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/40965988/
#Nephpearls #KidneyWk #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/40965988/